PUBLICATIONS

PUBLICATIONS

  • 10

    LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver

    ADVANCED MATERIALS. 2025. Impact factor: 26.8

    Seunghee Kim, Yeojin Kim, Sanjita Paudel, In Young Kang, Suyeon Kim, Jeesoo Kim,Sunmi Park, Seung-Hoi Koo, Hyun Sung Kim, Dae Won Jun,* Jinyoung Park,*Hyunbeom Lee,* and Joonseok Lee*

    Link
  • 9

    Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

    Clinical and Molecular Hepatology. 2022. Impact factor: 16.9

    Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

    Link
  • 8

    Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

    Clinical and Molecular Hepatology. 2022. Impact factor: 16.9

    Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

    Link
  • 7

    Discovering Heterogeneous Leukocytes Subsets Associated With Alcoholic Steatohepatitis by scRNAseq Analysis

    MedComm 2025. Impact factor: 10.7

    Haribalan Perumalsamy, Sehee Park, Ji Eun Kim, Xiao Xiao, Hye Young Kim, Dae Won Jun, Tae-Hyun Yoon

    Link
  • 6

    Necroptosis signaling in liver diseases: An update

    Pharmacol Res. 2019. Impact factor: 10.5

    Waqar Khalid Saeed, Dae Won Jun, Kiseok Jang, Dong Hee Koh

    Link
  • 5

    Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment

    Hepatobiliary Surg Nutr. 2019. Impact factor: 7.8

    Waqar K Saeed, Dae Won Jun

    Link
  • 4

    A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population

    Arch Pharm Res. 2025. Impact factor: 7.5

    Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun

    Link
  • 3

    Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids

    Antioxidants. 2025. Impact factor: 6.6

     Hye Young Kim, Ju Hee Oh, Hyun Sung Kim, Dae Won Jun

    Link
  • 2

    Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway

    World J Gastroenterol. 2025. Impact factor: 5.4

    Han-Ning Xuan Yuan, Hyun Sung Kim, Gye Ryeol Park, Jae Eun Ryu, Ji Eun Kim, In Young Kang, Hye Young Kim, Seung Min Lee, Ju Hee Oh, Eileen L Yoon, Dae Won Jun

    Link
  • 1

    Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease

    Nutrients. 2024. Impact factor: 5.0

    Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun

    Link